Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVT-004
- Development stage
- Preclinical
- Lead developer
- Travecta Therapeutics
- Modality
- Small Molecules
01
Overview
**TVT-004** is a proprietary conjugate of the endocannabinoid anandamide engineered using Travecta Therapeutics' mVECTA platform to cross the blood-brain barrier (BBB). It targets endocannabinoid pathways for non-opioid pain relief and has potential across a broad range of neurologic disorders, including neuralgia, multiple sclerosis, and neuroinflammation. Developed by Travecta Therapeutics, TVT-004 leverages insights into the Mfsd2a transporter to enable CNS penetration, with preclinical efficacy demonstrated against neurological targets; it was planned for clinical trials around 2021 as the company's lead asset.
02
Targets
MFSD2A (Major facilitator superfamily domain-containing protein 2A)
Beyond the preview
Go deeper on TVT-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVT-004.